Aquestive Therapeutics
AQST
177 hedge funds and large institutions have $467M invested in Aquestive Therapeutics in 2025 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 68 increasing their positions, 38 reducing their positions, and 21 closing their positions.
119% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 21
79% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 38
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
26% more capital invested
Capital invested by funds: $369M → $467M (+$97.2M)
16% more funds holding
Funds holding: 152 → 177 (+25)
11% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $11.4M
7.03% less ownership
Funds ownership: 66.24% → 59.21% (-7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.79M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.78M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$7.19M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$6.59M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$18.8M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$4.52M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.35M |
| 4 |
SCM
Sio Capital Management
New York
|
-$3.15M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.12M |
AQST Hedge Fund Activity: Q4 2025 in Review
177 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2025, worth a combined $467M — up 26% from $369M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new AQST positions and 21 closed out — a net gain of 25 holders — while 68 added to existing stakes and 38 trimmed.
The largest buyer was BlackRock, adding an estimated $7.79M. The largest seller was Perceptive Advisors, cutting an estimated $18.8M.
- 177 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2025, up from 152 in Q3 2025.
- Funds reported $467M of Aquestive Therapeutics stock for Q4 2025, up 26% quarter-over-quarter.
- 46 funds opened new Aquestive Therapeutics positions in Q4 2025 and 21 closed out, a net change of +25 holders.
- The largest Aquestive Therapeutics buyer in Q4 2025 was BlackRock, an estimated $7.79M added.
- The largest Aquestive Therapeutics seller in Q4 2025 was Perceptive Advisors, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2025.